Acute Respiratory Distress Syndrome Market to Grow Steadily at a 3.8% CAGR Through 2036, Supported by Emerging ARDS Therapies | DelveInsight

The ARDS market is projected to grow at a 3.8% CAGR through 2036, valued at USD 1.7 billion in 2025 across seven major markets. Growth is driven by rising ARDS incidence, advancements in critical care management, and the entry of emerging therapies including MultiStem, ExoFlo, ThyrOxy, and Gelsolin. Currently, no FDA-approved therapies specifically treat ARDS, with mechanical ventilation remaining the standard care approach.